0
Facebook
Volume 84 Issue 40 | p. 6 | Letters
Issue Date: October 2, 2006

Pharma industry

Department: Letters

I commend C&EN for the fine service it performed in publishing a full picture of the state of the pharmaceutical industry (C&EN, June 19, page 24). The reporting was probably not intended to paint this industry and its leaders as rogues, but what I saw was an industry that does the following: continues to raise its prices after recovering its sunk costs, something virtually unheard of elsewhere; buys off Congress to keep the government from bargaining on drug costs (Medicare Part D); introduces new, pricey drugs without any attempt to show advantage over medicines already on the market; fails to monitor new drugs for harmful side effects, as required by law; pays generic drugmakers to delay their entry; shows misleading advertising, such as the current strong sell of sleep medicines. Need I go on?

What a grim picture of corruption—from unfettered capitalism and doing anything not strictly illegal—to maximize profits. I missed any indication from the CEOs that they were going to do anything about these abuses.

Victor J. Reilly
Aiken, S.C.

 

Letters to the editor

C&EN encourages readers to contribute to this letters section. Please keep letters reasonably short-400 words or fewer. Letters are edited for clarity. Because of the heavy volume of mail received at C&EN, writers are limited to one letter in a six-month period. Letters may be submitted by e-mail at edit.cen@acs.org, fax (202) 872-8727, or regular mail (C&EN, 1155-16th St., N.W., Washington, DC 20036).

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society